It wouldn’t take much for Xi Jinping to cause massive and deadly disruptions to everyday life in the U.S.

Entresto generics have finally arrived in the U.S. in July, and approximately 9% of Novartis' revenue will be impacted. Learn ...

If you’ve spent any time looking into tech training institutes, you’ve probably come across greens technology placement ...

Janek Performance Group reports that custom sales training outperforms generic programs by aligning with specific team needs, ...

The US Food and Drug Administration (USFDA) approved a higher number of generic drugs in FY25, which ended on September 30, than it did in the previous year, signalling a steady appetite for ...

US President Donald Trump announced on Friday that his administration will impose a 100% tariff on branded and patented pharmaceuticals starting October 1, 2025, unless companies set up production in ...

President Donald Trump announced on Thursday (September 25, 2025) a 100% tariff on branded and patented pharmaceutical imports, effective October 1, 2025, unless companies establish manufacturing ...

Generics of Gilead Sciences' twice-yearly HIV pre-exposure prophylaxis (PrEP) Yeztugo (lenacapavir) are on the horizon, with India's Dr. Reddy’s Laboratories and Hetero Labs striking separate ...

In this article, we will be taking a look at the Top 10 AI-Powered Biotech Stocks to Buy Now. AbbVie Inc. stands second among them. AbbVie Inc. (NYSE:ABBV), a global biopharmaceutical leader known for ...

The Controller General of Patents, Designs and Trademarks (CGPDTM), the Indian Patent Office, has annulled the patent granted to Novartis for its cardiac drug Vymada, also sold internationally as ...

Biocon is aiming to support its generics business while complementing the momentum of its biosimilars segment. The company has expanded its U.S. operations with the opening of a manufacturing facility ...

“Overall, while Entresto generics are a headwind, there are other offsets, particularly Kisqali growth,” analysts said. Beyond Entresto, Goldman flagged a broader loss-of-exclusivity challenge.